Recruiting A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy NCT07047144 Conditions Anti-myostatin, Central Nervous System Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +17 more Locations Phoenix Children's Hospital — Phoenix, Arizona, United States Children's Hospital of Orange County (CHOC) — Orange, California, United States Stanford Neuroscience Health Center (SNHC) — Palo Alto, California, United States Children's Hospital Colorado — Aurora, Colorado, United States View all 25 locations View more locations Show fewer locations Loading locations... View Trial Details
Completed Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam NCT05156320 Conditions Anti-myostatin, Atrophy, Central Nervous System Diseases, +20 more Locations Children's of Alabama — Birmingham, Alabama, United States Phoenix Children's Hospital — Phoenix, Arizona, United States Children's Hospital of Los Angeles — Los Angeles, California, United States Stanford University Medical Center — Palo Alto, California, United States View all 50 locations View more locations Show fewer locations Loading locations... View Trial Details
Active, Not Recruiting Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab NCT05626855 Conditions Anti-myostatin, Atrophy, Central Nervous System Diseases, +20 more Locations Phoenix Childrens Hospital — Phoenix, Arizona, United States UCSD Altman Clinical and Translational Research — La Jolla, California, United States Children's Hospital Los Angeles — Los Angeles, California, United States Stanford Neuroscience Health Center — Palo Alto, California, United States View all 49 locations View more locations Show fewer locations Loading locations... View Trial Details
